Topic:

R&D

Latest Headlines

Latest Headlines

Tekmira changes its name and shuffles away from Ebola

Tekmira Pharmaceuticals is shifting focus after years of up-and-down development, planning to change its name and train its attention on hepatitis B.

Exelixis soars as a once-failed cancer drug comes through in Phase III

Exelixis notched a crucial clinical success for its top oncology prospect, meeting its goals in a kidney cancer trial and clearing the way for a lucrative FDA nod.

UPDATED: Bristol-Myers flags early success for PhIII Opdivo study in kidney cancer

Bristol-Myers Squibb flagged an early success for its Phase III Opdivo (nivolumab) study for kidney cancer, saying that an independent monitoring group concluded that its closely watched checkpoint inhibitor has beat Afinitor (everolimus) in improving overall survival for advanced patients.

Vermillion raises $18.8M to fund escalation of bioinformatics ambitions

Vermillion has tapped investors for money to fund the enhancement of its bioinformatics platform. The diagnostics and bioanalytics player pulled in a total of $18.8 million through a stock offering, a slice of which will be ploughed into biotech IT.

Illumina wraps lab automation and software around HiSeq X to lower barrier to mass sequencing

Illumina has introduced a suite of tools and software to help research organizations new to population-scale sequencing to get started with its HiSeq X Ten and Five systems. The move comes one month after BGI joined the large-scale sequencing field with a package that covers each step of the process, from sample preparation to data analysis.

Amgen's latest immuno-oncology drug comes through in Phase II

Amgen's new immuno-oncology treatment demonstrated promising efficacy in a midstage trial on a rare blood cancer.

Aerie plots an R&D expansion after an FDA rebound for its lead drug

Aerie Pharmaceuticals, regaining momentum after a costly clinical setback, is planning to expand its R&D operation in North Carolina, pressing forward with a treatment for glaucoma.

Singapore's big biotech push yields its first clinical contender

Singapore, a nation working to raise its profile in the biopharma world, has kicked off the first-ever clinical trial of a locally invented drug, working with Duke University on a novel cancer treatment it hopes will spur more R&D.

Lilly and Biogen prep make-or-break Alzheimer's data amid an amyloid renaissance

Biogen and Eli Lilly, two drugmakers making big bets in Alzheimer's disease, are set to present clinical data on a pair of much-scrutinized projects with potential to change the industry's approach to the field.

BD opens new diabetes R&D center to develop, manufacture next-gen products

Becton Dickinson has opened the doors of a new facility in Andover, MA, that's dedicated to R&D and manufacturing for novel products to better address the needs of Type 1 and Type 2 diabetes patients. The center is part of a renewed effort for BD in diabetes, after it has suffered difficulties due to pricing erosion.